Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLIX1 + PARP inhibitor
- Development stage
- Unknown
- Lead developer
- Hemispherian
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GLIX1 + PARPi is an experimental combination therapy being developed by Hemispherian for the treatment of glioblastoma (GBM). The combination consists of GLIX1, a small molecule activator of the TET2 (Ten-Eleven Translocation 2) enzyme, and a PARP (Poly ADP-ribose polymerase) inhibitor. GLIX1 works by restoring levels of 5-hydroxymethylcytosine (5hmC), an epigenetic mark that is frequently lost in cancer cells, which increases their susceptibility to DNA damage. By inhibiting PARP-mediated DNA repair in this sensitized state, the combination aims to enhance the accumulation of lethal DNA lesions specifically within tumor cells. This therapeutic strategy is designed to overcome resistance in high-grade gliomas and is currently being evaluated in Phase 1/2 clinical studies.
- Other names
- GLIX1 + PARPi
02
Targets
TET2 (Methylcytosine dioxygenase TET2)PARP (PARP family)
Beyond the preview
Go deeper on GLIX1 + PARP inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLIX1 + PARP inhibitor.